Actualités et publications - CIC Henri-Mondor

Publications

Chen AP, O’Sullivan Coyne G, Wolters PL, Wolkenstein P. Clinical benefits of selumetinib in adults with neurofibromatosis type 1 – Authors’ reply. Lancet. 2025 Dec 13;406(10521):2754-2755. doi: 10.1016/S0140-6736(25)02248-2. PMID: 41390208.

Peyrottes A, Auclin E, Timsit MO, Branger N, Doumerc N, Waeckel T, Bigot P, Surlemont L, Knipper S, Pignot G, Bruyère F, Fontenil A, Parier B, Champy C, Rouprêt M, Patard JJ, Henon F, Fiard G, Guillotreau J, Beauval JB, Michel C, Bernardeau S, Taha F, Mallet R, Panthier F, Guy L, Vignot L, Khene ZE, Bernhard JC, Méjean A, Audenet F. Clinical and Pathological Features Associated with Chromophobe Renal Cell Carcinoma Recurrence: Analysis from a Nationwide Cohort. Eur Urol Open Sci. 2025 Nov 13;82:185-191. doi: 10.1016/j.euros.2025.10.023. PMID: 41322956; PMCID: PMC12663658.

Deluegue L, Margue G, Cadart L, Bernhard JC, Bensalah K, Bigot P, Doumerc N, Bruyere F, Roupret M, Branger N, Surlemont L, Champy C, Parier B, Paparel P, Waeckel T, Lang H, Michel C, Fontenil A, Beauval JB, Patard JJ, Vallee M, Guillotreau J, Traxer O, Guy L, Audenet F, Rouget B, Olivier J, Fantoni JC. Local recurrence after R0 partial nephrectomy for RCC: insights from a large multicenter cohort (PREPARE study – UroCCR 140). World J Urol. 2025 Nov 26;44(1):3. doi: 10.1007/s00345-025-06093-3. PMID: 41296078.

Fertitta L, Sarin KY, Romo CG, Bergqvist C, Blakeley JO, Peiffer B, Tran VT, Armand ML, Moryousef S, Ferkal S, Le Corvoisier P, Ezzedine K, Wolkenstein P. Stigmatization related to cutaneous neurofibromas in neurofibromatosis 1: Development, validation and severity strata of the cNF-PUSH-D. Br J Dermatol. 2025 Nov 26:ljaf479. doi: 10.1093/bjd/ljaf479. Epub ahead of print. PMID: 41290043.

Hoisnard L, Sbidian E. Infectious risk with JAKi: What about atopic dermatitis? J Eur Acad Dermatol Venereol. 2025 Dec;39(12):2024-2025. doi: 10.1111/jdv.70116. PMID: 41287441.

Ouakrat R, Penso L, Jullien D, Sokol H, Sbidian E. Antibiotic Use and the Persistence of Biologic Therapies in Patients With Psoriasis. JAMA Dermatol. 2026 Jan 1;162(1):55-59. doi: 10.1001/jamadermatol.2025.4427. PMID: 41222929; PMCID: PMC12613086.

Onfroy A, Jean-Louis F, Le Corvoisier P, Coulpier F, Muret K, Bonnet E, Arrouasse R, Boucle C, Abid S, Sbidian E, Bergqvist C, Wolkenstein P, Godot V, Deleuze JF, Lévy Y, Topilko P, Audureau E, Hue S. Hair follicle stem cell fate supports distinct clinical endotypes in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2025 Nov 6. doi: 10.1111/jdv.70152. Epub ahead of print. PMID: 41195937.

Fertitta L, Jannic A, Bergqvist C, Delique V, Armand ML, Moryousef S, Ferkal S, Zehou O, Ayache H, Le Corvoisier P, Audureau E, Hebrard B, Lunati-Rozie A, Funalot B, Sarin KY, Blakeley JO, Romo CG, Berman Y, Le LQ, Ezzedine K, Wolkenstein P; FIMARAD group. Measurement of the severity related to cutaneous neurofibromas in neurofibromatosis type 1: Development and validation of the Nef-ASI. J Am Acad Dermatol. 2026 Feb;94(2):641-644. doi: 10.1016/j.jaad.2025.10.025. Epub 2025 Oct 6. PMID: 41061983.

Chenain L, Fabre A, Titeux H, Morgado G, Youssov K, Clavel C, Bachoud-Lévi AC. Emotional speech markers of psychiatric disturbance in Huntington’s disease. Front Psychiatry. 2025 Aug 12;16:1633492. doi: 10.3389/fpsyt.2025.1633492. PMID: 40873677; PMCID: PMC12378116.

Chen AP, Coyne GO, Wolters PL, Martin S, Farschtschi S, Blanco I, Chen Z, Darrigo LG Jr, Eoli M, Whittle JR, Nishida Y, Lamarca R, de la Rosa Rodriguez R, Adeyemi A, Herrero I, Llorente N, Diede SJ, Dombi E, Wolkenstein P; KOMET study investigators. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet. 2025 Jun 21;405(10496):2217-2230. doi: 10.1016/S0140-6736(25)00986-9. Epub 2025 Jun 2. PMID: 40473450; PMCID: PMC12285420.

Nishioka K, Kawamura M, Iima M, Ueda D, Ito R, Saida T, Kurokawa R, Takumi K, Sakata A, Ide S, Honda M, Yanagawa M, Sugawara S, Oda S, Watabe T, Sofue K, Hirata K, Naganawa S. The glymphatic system in oncology: from the perspective of a radiation oncologist. J Radiat Res. 2025 Jul 22;66(4):343-353. doi: 10.1093/jrr/rraf027. PMID: 40460451; PMCID: PMC12283521.

Mengeot L, Pasmant E, Fontbonne A, Tounian P, Ayache H, Ferkal S, Peiffer B, Ezzedine K, Vidaud D, Wolkenstein P, Fertitta L. Lower Prevalence of Overweight and Obesity in Adults with Neurofibromatosis. J Invest Dermatol. 2025 Nov;145(11):2908-2911.e1. doi: 10.1016/j.jid.2025.04.026. Epub 2025 May 13. PMID: 40373955.

Jourdain H, Hoisnard L, Sbidian E, Zureik M. Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System. World J Pediatr. 2025 Jan;21(1):62-72. doi: 10.1007/s12519-024-00873-4. Epub 2025 Jan 23. PMID: 39849273.

Bettuzzi T, Lebrun-Vignes B, Assier H, Pina Vegas L, Ingen-Housz-Oro S, Sbidian E. Recurrences and rechallenges of suspected drugs in patients with epidermal necrolysis. Clin Exp Dermatol. 2025 May 23;50(6):1116-1124. doi: 10.1093/ced/llae553. PMID: 39760897.

Dalléry R, Fraisse N, Cléret de Langavant L, Youssov K, Morgado G, Massart R, Schubert R, Reilmann R, Jacquemot C, Bapst B, Busse M, Craufurd D, Rosser A, Lunven M, Bachoud-Lévi AC. The joint memory effect: challenging the selfish stigma in Huntington’s disease? Brain Commun. 2024 Dec 9;7(1):fcae440. doi: 10.1093/braincomms/fcae440. PMID: 39744082; PMCID: PMC11693399.

Penso L, Touvier M, Srour B, Ezzedine K, Sbidian E. Ultraprocessed Food Intake and Psoriasis. JAMA Dermatol. 2025 Jan 1;161(1):105-108. doi: 10.1001/jamadermatol.2024.4832. PMID: 39602129; PMCID: PMC11736505.

Gauckler P, Matyjek A, Kapsia S, Marinaki S, Quintana LF, Diaz MM, King C, Griffin S, Ramachandran R, Odler B, Eller K, Artan AS, Mirioglu S, Busch M, Schaepe M, Turkmen K, Cheung CK, Pepper RJ, Juarez GF, Pascual J, Auñón P, García-Carro C, Rodriguez A, Alberici F, Luzardo L, Chebotareva N, Schönermarck U, Fernández L, Radhakrishnan J, Guaman K, Peleg Y, Hoisnard L, Audard V, Papasotiriou M, Krnanska N, Tesar V, Hruskova Z, Bruchfeld A, Stangou M, Lioulios G, Faguer S, Ribes D, Salhi S, Windpessl M, Galešić K, Crnogorac M, Zagorec N, Mayer G, Kronbichler A; RITERM Study Team. Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies. J Am Soc Nephrol. 2025 Apr 1;36(4):668-678. doi: 10.1681/ASN.0000000520. Epub 2024 Oct 16. PMID: 39431468; PMCID: PMC11975237.

Bettuzzi, Thomas et al. “Incidence, In-Hospital and Long-Term Mortality, and Sequelae of Epidermal Necrolysis in Adults.”
JAMA dermatology, e243575. 2 Oct. 2024, doi:10.1001/jamadermatol.2024.3575

Nicol, Edith et al. “Preformulation evaluation of selumetinib for topical application: skin distribution and photodegradation analysis using MALDI imaging and LC-MS/MS.”
Pharmaceutical development and technology vol. 29,8 (2024): 855-861. doi:10.1080/10837450.2024.2405829

Pacot, Laurence et al. “Prenatal diagnosis for neurofibromatosis type 1 and the pitfalls of germline mosaics.”
NPJ genomic medicine vol. 9,1 41. 8 Sep. 2024, doi:10.1038/s41525-024-00425-9

Leboyer, Marion et al. “Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial.”
Brain, behavior, and immunity, vol. 123 177-184. 4 Sep. 2024, doi:10.1016/j.bbi.2024.09.005

Fontana, Marianna et al. “Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.”
The New England journal of medicine, 10.1056/NEJMoa2409134. 30 Aug. 2024, doi:10.1056/NEJMoa2409134

Skorobogatov, Katrien et al. “Immune-based Machine learning Prediction of Diagnosis and Illness State in Schizophrenia and Bipolar Disorder.”
Brain, behavior, and immunity vol. 122 (2024): 422-432. doi:10.1016/j.bbi.2024.08.013

Pina Vegas, Laura et al. “Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS).”
RMD open vol. 10,3 e004631. 7 Aug. 2024, doi:10.1136/rmdopen-2024-004631

Boukouaci, Wahid et al. “B Cell-activating factor (BAFF): A promising trans-nosographic biomarker of inflammation and autoimmunity in bipolar disorder and schizophrenia.”
Brain, behavior, and immunity vol. 121 (2024): 178-188. doi:10.1016/j.bbi.2024.07.025

ISO 9001

Le CIC s’engage dans une démarche qualité conforme à la norme ISO 9001 : 2015 visant à formaliser et structurer son Système de Management de la Qualité. Dans la continuité des actions engagées depuis 2024, notamment l’obtention du label hospitalité le CIC place l’amélioration continue au cœur de ses activités d’investigation clinique. Cet engagement se traduit par le respect des exigences réglementaires et éthiques, la garantie de la sécurité et du bien-être des patients, ainsi que la satisfaction des partenaires et collaborateurs impliqués dans les projets de recherche clinique.